Paulson KG, et al. Incidence, demographics, and survival of malignant hemangioendothelioma in the United States. Cancer Med. 2023;12:15101–6.
Article PubMed PubMed Central Google Scholar
Stacchiotti S, et al. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open. 2021;6:100170.
Article CAS PubMed PubMed Central Google Scholar
Shiba S, et al. Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study. BMC Cancer. 2018;18:993.
Article CAS PubMed PubMed Central Google Scholar
Errani C, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosome Cancer. 2011;50:644–53.
Tanas MR, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med. 2011;3:98ra82-98ra82.
Antonescu CR, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosome Cancer. 2013;52:775–84.
Shibuya R, et al. CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma. Histopathology. 2015;67:827–35.
Rosenbaum E, et al. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Mod Pathol Off J U S Can Acad Pathol Inc. 2020;33:591–602.
Zhang H, et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem. 2009;284:13355–62.
Article CAS PubMed PubMed Central Google Scholar
Liu C-Y, et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFβ-TrCP E3 ligase. J Biol Chem. 2010;285:37159–69.
Article CAS PubMed PubMed Central Google Scholar
Hansen CG, Ng YLD, Lam W-LM, Plouffe SW, Guan K-L. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1. Cell Res. 2015;25:1299–313.
Article CAS PubMed PubMed Central Google Scholar
Xu H, et al. MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells. Cell Death Differ. 2019;26:2400–15.
Article CAS PubMed PubMed Central Google Scholar
Pulkkinen HH, et al. BMP6/TAZ-Hippo signaling modulates angiogenesis and endothelial cell response to VEGF. Angiogenesis. 2021;24:129–44.
Article CAS PubMed Google Scholar
Stacchiotti S, et al. Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: a case-series analysis within the Italian Rare Cancer Network. Cancer. 2021;127:569–76.
Article CAS PubMed Google Scholar
Driskill JH, et al. WWTR1(TAZ)-CAMTA1 reprograms endothelial cells to drive epithelioid hemangioendothelioma. Genes Dev. 2021;35:495–511.
Article CAS PubMed PubMed Central Google Scholar
Seavey CN, et al. WWTR1(TAZ)-CAMTA1 gene fusion is sufficient to dysregulate YAP/TAZ signaling and drive epithelioid hemangioendothelioma tumorigenesis. Genes Dev. 2021;35:512–27.
Article CAS PubMed PubMed Central Google Scholar
Hu EY, et al. Image-guided percutaneous ablation of hepatic epithelioid hemangioendothelioma. Abdom Radiol N Y. 2024;49:1241–7.
Vidal-Jove J, et al. First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study. Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group. 2022;39:1115–23.
Mendiratta-Lala M, et al. The #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors. Radiology. 2024;312:e233051.
Stacchiotti S, Tap W, Leonard H, Zaffaroni N, Baldi GG. New molecular insights, and the role of systemic therapies and collaboration for treatment of epithelioid hemangioendothelioma (EHE). Curr Treat Options Oncol. 2023;24:667–79.
Frezza AM, et al. Systemic therapies in advanced epithelioid haemangioendothelioma: a retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Med. 2021;10:2645–59.
Article CAS PubMed PubMed Central Google Scholar
Cioffi A, et al. Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival. J Clin Oncol. 2011;29:10079–10079.
Yousaf N, et al. Systemic treatment options for epithelioid haemangioendothelioma: the Royal Marsden Hospital experience. Anticancer Res. 2015;35:473–80.
Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol. 2010;22:351–5.
Article CAS PubMed Google Scholar
Sampat KR, O’Neil B. Antiangiogenic therapies for advanced hepatocellular carcinoma. Oncologist. 2013;18:430–8.
Article CAS PubMed PubMed Central Google Scholar
Agulnik M, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:257–63.
Dhillon S. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. BioDrugs Clin Immunother Biopharm Gene Ther. 2013;27:375–92.
Belmont L, Zemoura L, Couderc LJ. Pulmonary epithelioid haemangioendothelioma and bevacizumab. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2008;3:557–8.
Telli TA, et al. VEGF-VEGFR pathway seems to be the best target in hepatic epithelioid hemangioendothelioma: a case series with review of the literature. Curr Probl Cancer. 2020;44:100568.
Tolkach Y, Petrov S, Lerut E, Van Poppel H. Epithelioid hemangioendothelioma of the kidney treated with sunitinib. Onkologie. 2012;35:376–8.
Article CAS PubMed Google Scholar
Saada E, Saint Paul M-C, Gugenheim J, Follana P, François E. Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate. Oncol Res Treat. 2014;37:124–6.
Chevreau C, et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer. 2013;119:2639–44.
Article CAS PubMed Google Scholar
Kumar R, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6:2012–21.
Article CAS PubMed Google Scholar
van der Graaf WT, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2012;379:1879–86.
Bally O, et al. Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma. Clin Sarcoma Res. 2015;5:12.
Comments (0)